Rob Webster

2.9k total citations · 1 hit paper
26 papers, 2.1k citations indexed

About

Rob Webster is a scholar working on Molecular Biology, Infectious Diseases and Virology. According to data from OpenAlex, Rob Webster has authored 26 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 6 papers in Infectious Diseases and 5 papers in Virology. Recurrent topics in Rob Webster's work include HIV/AIDS drug development and treatment (6 papers), HIV Research and Treatment (5 papers) and Pharmacogenetics and Drug Metabolism (4 papers). Rob Webster is often cited by papers focused on HIV/AIDS drug development and treatment (6 papers), HIV Research and Treatment (5 papers) and Pharmacogenetics and Drug Metabolism (4 papers). Rob Webster collaborates with scholars based in United Kingdom, United States and Netherlands. Rob Webster's co-authors include Manos Perros, Anthony Wood, David A. Price, Mike Westby, Malcolm Macartney, Blanda Stammen, Patrick Dorr, Duncan Armour, Julie Mori and Paul Griffin and has published in prestigious journals such as Blood, Antimicrobial Agents and Chemotherapy and Journal of Pharmaceutical Sciences.

In The Last Decade

Rob Webster

26 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity

2005 909 citations Mike Westby, Rob Webster et al. profile →

Peers

Countries citing papers authored by Rob Webster

Since Specialization

Citations

This map shows the geographic impact of Rob Webster's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rob Webster with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rob Webster more than expected).

Fields of papers citing papers by Rob Webster

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rob Webster. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rob Webster. The network helps show where Rob Webster may publish in the future.

Co-authorship network of co-authors of Rob Webster

This figure shows the co-authorship network connecting the top 25 collaborators of Rob Webster. A scholar is included among the top collaborators of Rob Webster based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rob Webster. Rob Webster is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Induction and Impact of Anti-Drug Responses Elicited by a Human Recombinant Coagulation Factor FXaI16L in Preclinical Species 2019 ·The AAPS Journal ·Chuenlei Parng, Michael W. Bolt, Debra D. Pittman, (unknown), (unknown), Boris Gorovits, Rob Webster	3
2	Translational Pharmacokinetic/Pharmacodynamic Characterization and Target-Mediated Drug Disposition Modeling of an Anti–Tissue Factor Pathway Inhibitor Antibody, PF-06741086 2018 ·Journal of Pharmaceutical Sciences ·Chuenlei Parng, (unknown), Debra D. Pittman, Katherine Wright, (unknown), Sunita Patel–Hett, (unknown), (unknown), Marjorie A. Peraza, Dawn Dufield, John E. Murphy, Rob Webster	28
3	Quantitative Biodistribution of Biotherapeutics at Whole Body, Organ and Cellular Levels by Autoradiography 2018 ·Bioanalysis ·Mengmeng Wang, Yutian Zhan, Shawn P. O’Neil, Stephen Harris, (unknown), Andrew McEwen, Rob Webster, Denise M. O’Hara	9
4	Clinical Micro-Dose Studies to Explore the Human Pharmacokinetics of Four Selective Inhibitors of Human Nav1.7 Voltage-Dependent Sodium Channels 2016 ·Clinical Pharmacokinetics ·Hannah M. Jones, Richard P. Butt, Rob Webster, Ian Gurrell, Paweł Dżygiel, (unknown), Daniela Fraier, (unknown), Laura Iavarone, (unknown), (unknown), Alex Phipps, (unknown), (unknown), Kevin Beaumont	22
5	CD8+ T Lymphocyte Epitopes From The Herpes Simplex Virus Type 2 ICP27, VP22 and VP13/14 Proteins To Facilitate Vaccine Design And Characterization 2013 ·Cells ·(unknown), (unknown), (unknown), Helen Bright, Paul Cockle, (unknown), Rob Webster, Brian Champion, Timothy P. Hickling, Fareed Mirza	4
6	Disposition of Biologics 2012 ·Advances in pharmacology ·Kevin Brady, Rob Webster	6
7	Medicinal chemistry approaches to avoid aldehyde oxidase metabolism 2012 ·Bioorganic & Medicinal Chemistry Letters ·David C. Pryde, Thien-Duc Tran, Peter Jones, (unknown), Martin Howard, Iain Gardner, Ruth Hyland, Rob Webster, (unknown), Sharan K. Bagal, Kiyoyuki Omoto, Richard Schneider, Jian Lin	31
8	A comprehensive non‐clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder 2011 ·British Journal of Clinical Pharmacology ·Ernesto Callegari, Bimal Malhotra, Peter J. Bungay, Rob Webster, Katherine S. Fenner, Sarah Kempshall, Jennifer L. LaPerle, Martin C. Michel, Gary G. Kay	111
9	Species differences in the multiple-dose pharmacokinetics of the non-nucleoside reverse transcriptase inhibitor (NNRTI) UK-453,061 in animals and man: implications for safety considerations 2009 ·Xenobiotica ·Don K. Walker, John D. Davis, Christopher Houle, I. Gardner, Rob Webster	10
10	Pyrazole NNRTIs 1: Design and initial optimisation of a novel template 2009 ·Bioorganic & Medicinal Chemistry Letters ·Charles E. Mowbray, Catherine Burt, Romuald Corbau, Manos Perros, (unknown), Paul A. Stupple, Rob Webster, Anthony Wood	30
11	Pyrazole NNRTIs 3: Optimisation of physicochemical properties 2009 ·Bioorganic & Medicinal Chemistry Letters ·Charles E. Mowbray, Romuald Corbau, Michael L. Hawes, Lyn H. Jones, James E. Mills, Manos Perros, Matthew D. Selby, Paul A. Stupple, Rob Webster, Anthony Wood	24
12	Pyrazole NNRTIs 4: Selection of UK-453,061 (lersivirine) as a Development Candidate 2009 ·Bioorganic & Medicinal Chemistry Letters ·Charles E. Mowbray, Catherine Burt, Romuald Corbau, (unknown), Michael L. Hawes, Manos Perros, (unknown), David A. Price, (unknown), Matthew D. Selby, Paul A. Stupple, Rob Webster, Anthony Wood	91
13	Prediction of Human Pharmacokinetics From Preclinical Information: Comparative Accuracy of Quantitative Prediction Approaches 2009 ·The Journal of Clinical Pharmacology ·Natilie Hosea, Wendy T. Collard, Susan Cole, Tristan S. Maurer, (unknown), Hannah M. Jones, Shefali Kakar, Yasuhiro Nakai, Bill J. Smith, Rob Webster, Kevin Beaumont	205
14	The discovery of adamantyl-derived, inhaled, long acting β2-adrenoreceptor agonists 2008 ·Bioorganic & Medicinal Chemistry Letters ·Alan D. Brown, Mark E. Bunnage, Paul A. Glossop, Kim James, Rhys Jones, (unknown), Russell A. Lewthwaite, Simon J. Mantell, Christelle Perros-Huguet, David A. Price, Mike Trevethick, Rob Webster	28
15	Optimization of 5‐Aryloxyimidazole Non‐Nucleoside Reverse Transcriptase Inhibitors 2008 ·ChemMedChem ·Lyn H. Jones, (unknown), Romuald Corbau, Duncan A. Hay, Donald S. Middleton, Charles E. Mowbray, (unknown), Manos Perros, Amy Randall, (unknown), Rob Webster, Mike Westby, David J. Williams	8
16	Impact of Physicochemical and Structural Properties on the Pharmacokinetics of a Series of α1L-Adrenoceptor Antagonists 2007 ·Drug Metabolism and Disposition ·Alison Betts, (unknown), Iain Gardner, David A. Fox, Rob Webster, Kevin Beaumont, Paul Morgan	5
17	The discovery of long acting β2-adrenoreceptor agonists 2007 ·Bioorganic & Medicinal Chemistry Letters ·Alan D. Brown, Mark E. Bunnage, Paul A. Glossop, Kim James, Rhys D.O. Jones, (unknown), Russell A. Lewthwaite, Simon J. Mantell, Christelle Perros-Huguet, David A. Price, Mike Trevethick, Rob Webster	29
18	The discovery of indole-derived long acting β2-adrenoceptor agonists for the treatment of asthma and COPD 2007 ·Bioorganic & Medicinal Chemistry Letters ·Alan D. Brown, Mark E. Bunnage, Paul A. Glossop, Mark Holbrook, Rhys D.O. Jones, (unknown), Russell A. Lewthwaite, Simon J. Mantell, Christelle Perros-Huguet, David Price, Rob Webster	22
19	PEGylated Proteins: Evaluation of Their Safety in the Absence of Definitive Metabolism Studies 2006 ·Drug Metabolism and Disposition ·Rob Webster, (unknown), Philip L. Harris, Ned R. Siegel, Jeanne Stadler, Lorraine Tilbury, Dennis A. Smith	271
20	Pharmacokinetic/pharmacodynamic assessment of the effects of E4031, cisapride, terfenadine and terodiline on monophasic action potential duration in dog 2001 ·Xenobiotica ·Rob Webster, (unknown), (unknown), Annie Harrison, (unknown), (unknown), J.B. Phipps, Don K. Walker	35

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact